Registered title, quoted from ClinicalTrials.gov
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 9 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 10
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
- Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
- Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
- Study siteFirst Affiliated Hospital of Kunming Medical University昆明医科大学第一附属医院KunmingHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
- Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
- Study siteXijing Hospital空军军医大学西京医院Xi'anHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07663253, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Absolute neutrophil count (ANC) ≥1.0×10⁹/L
Inclusion criterion 4
Platelet count ≥50×10⁹/L
Inclusion criterion 5
Calculated creatinine clearance ≥30 mL/min (using Cockcroft-Gault formula)
Inclusion criterion 6
Total bilirubin ≤3× upper limit of normal (ULN)
Inclusion criterion 7
Active infectious disease, known human immunodeficiency virus (HIV) positivity, active hepatitis B or hepatitis C
Exclusion criterion 10
Patients who are currently pregnant
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07663253, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years
- Newly diagnosed transplant-ineligible multiple myeloma patients as assessed by investigator, specifically referring to CSCO guidelines
- Must meet corresponding laboratory test results (refer to restrictions in package inserts of combination drugs):
- Absolute neutrophil count (ANC) ≥1.0×10⁹/L
- Platelet count ≥50×10⁹/L
- Calculated creatinine clearance ≥30 mL/min (using Cockcroft-Gault formula)
- Total bilirubin ≤3× upper limit of normal (ULN)
- TI-NDMM patients intended for Isa-VRd regimen treatment as determined by investigator judgment, independent of study objectives Signed informed consent form (by patient or their legal representative)
Exclusion Criteria:
- Patients currently participating in other interventional clinical studies
- Patients with known severe hypersensitivity reactions to Isatuximab or any other excipients
- Severe bacteremia at the time of administration
- Currently uncontrolled cardiovascular disease, including:
- Uncontrolled hypertension
- Uncontrolled arrhythmia
- Uncontrollable congestive heart failure
- Unstable angina
- Patients with peripheral neuropathy ≥Grade 2
- Active infectious disease, known human immunodeficiency virus (HIV) positivity, active hepatitis B or hepatitis C
- Patients who are currently pregnant
- Patients who, at the physician's discretion, are unable to tolerate any drug in the combination regimen
Quoted from ClinicalTrials.gov, NCT07663253, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07663253, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.